en · de · es · fr · pt
tb-500-notes.peptides7250.com › Topic › Identity And Naming Background — Research Overview

Identity And Naming Background — Research Overview

By Editorial Desk · published 2026-04-02 · last reviewed 2026-05-25 · Topic

The short version of reconstitution fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-05-25. Anything still debated is marked as such rather than presented as settled.

Identity And Naming Background

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

Storage and Analytical Verification

Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.

Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.

Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderSupplied as a lyophilised cake in sealed vials
Solubility classFreely soluble in waterPolar and charged side chains dominate the sequence
Typical storage temperature-20 °C or belowDry and dark; a desiccant is often recommended
Identity confirmationMass spectrometryObserved mass compared with the theoretical value
Common synonymsThymosin beta-4 fragmentAlso written as T beta 4 fragment 17-23

TB-500 Background and Identity

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

Related pages on this site

TB-500 Identity and Chemical Background

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

Notes from published material

In May 2026, the federal election watchdog announced Findlay was under investigation over expenses for her failed re-election bid. Elections Canada alleges Findlay received $75,000 in undeclared and unpaid services from a corporation in exchange for promised federal contracts. They further suggest that approximately 50 individuals described as foreign nationals without legal status, canvassed on behalf of Findlay. In response, Findlay threatened legal action against the media for publishing any story mentioning these allegations.

== Signs and symptoms == Rheumatoid arthritis (RA) is a chronic autoimmune disorder that can affect multiple organ systems. It mainly affects fluid filled connections between joints (synovial joints), causing inflammation, pain, and stiffness in the joints. RA also affects other organs in 20–40% of people. RA typically develops slowly and affects both sides of the body. Systemic symptoms such as fatigue, low-grade fevers and weight loss are also seen in RA.

== Multiple valves == Multiple check valves can be connected in series. For example, a double check valve is often used as a backflow prevention device to keep potentially contaminated water from siphoning back into municipal water supply lines. There are also double ball check valves in which there are two ball/seat combinations sequentially in the same body to ensure positive leak-tight shutoff when blocking reverse flow; and piston check valves, wafer check valves, and ball-and-cone check valves.

=== Saprotrophic === Buna-shimeji (ブナシメジ, lit. beech shimeji), Hypsizygus tessulatus, also known in English as the brown beech or brown clamshell mushroom. Hypsizygus marmoreus is a synonym of Hypsizygus tessulatus. Cultivation of Buna-shimeji was first patented by Takara Shuzo Co., Ltd. in 1972 as hon-shimeji and the production started in 1973 in Japan. Now, several breeds are widely cultivated and sold fresh in markets. Bunapi-shimeji (ブナピー), known in English as the white beech or white clamshell mushroom. Bunapi was selected from UV-irradiated buna-shimeji ('hokuto #8' x 'hokuto #12') and the breed was registered as 'hokuto shiro #1' by Hokuto Corporation. Hatake-shimeji (ハタケシメジ), Lyophyllum decastes. Shirotamogidake (シロタモギダケ), Hypsizygus ulmarius. These two species had been also sold as hon-shimeji. Velvet pioppino (alias velvet pioppini, black poplar mushroom, Chinese: 茶樹菇/茶树菇), Agrocybe aegerita.

Sources: en.wikipedia.org

Further detail

The first isolation of deoxyribonucleic acid (DNA) was done in 1869 by Friedrich Miescher. DNA extraction is the process of isolating DNA from the cells of an organism isolated from a sample, typically a biological sample such as blood, saliva, or tissue. It involves breaking open the cells, removing proteins and other contaminants, and purifying the DNA so that it is free of other cellular components. The purified DNA can then be used for downstream applications such as PCR, sequencing, or cloning. Currently, it is a routine procedure in molecular biology or forensic analyses. This process can be done in several ways, depending on the type of the sample and the downstream application, the most common methods are: mechanical, chemical and enzymatic lysis, precipitation, purification, and concentration. The specific method used to extract the DNA, such as phenol-chloroform extraction, alcohol precipitation, or silica-based purification. For the chemical method, many different kits are used for extraction, and selecting the correct one will save time on kit optimization and extraction procedures. PCR sensitivity detection is considered to show the variation between the commercial kits. There are many different methods for extracting DNA, but some common steps include:

radionuclide Also radioisotope. A radioactive nuclide of a specified element, especially a particular isotope of that element which characteristically undergoes spontaneous decay into one or more stable nuclides by emitting excess energy from the nucleus.

== Function == TIG1's specific functions are still being elucidated. Latexin is a structurally similar protein to TIG1. Latexin is the only mammalian carboxypeptidase inhibitor, although TIG1's proteolytic activity remains unexplored. Using a selective subtractive differential gene display, Jing and colleagues discovered that TIG1 expression was absent from malignant prostate carcinoma cell lines but present in benign tumor lines. When highly malignant prostate cancer cells were transfected with TIG1, decreased in vitro invasiveness was measured using an extracellular matrix migration assay over a period of 48 hours. This same group of scientists performed another experiment in which TIG1 expression was restored in mice that were homozygous for the deletion of the TIG1 gene. Although the restoration of TIG1 did not prevent tumor growth in these mice, the average size of the tumors showed a 2.4-fold decrease (Jing et al., 2006).

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.

Where does the sequence LKKTETQ come from?

It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.

Is TB-500 an approved medicine?

It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.

How is the powder stored before use?

Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.

Network